AbbVie (ABBV) Stock Forecast & Price Target

$256.08 -2.07 (-0.80%)

As of 03:58 PM Eastern

Compare

AbbVie - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
0

Hold
5

Buy
21

Based on 26 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 5 have given a hold rating, 19 have given a buy rating, and 2 have given a strong buy rating for ABBV.

Consensus Price Target

$275.95
7.76% Upside

According to the 26 analysts' twelve-month price targets for AbbVie, the average price target is $275.95. The highest price target for ABBV is $303.00, while the lowest price target for ABBV is $223.00. The average price target represents a forecasted upside of 7.76% from the current price of $256.08.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABBV Analyst Ratings Over Time

Type	Current Forecast 8/28/25 to 8/28/26	1 Month Ago 7/29/25 to 7/29/26	3 Months Ago 5/30/25 to 5/30/26	1 Year Ago 8/28/24 to 8/28/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)
Buy	19 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$275.95	$268.10	$253.43	$214.70
Forecasted Upside	7.76% Upside	1.71% Upside	16.34% Upside	3.27% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Healthcare Companies	Broader Market
Consensus Rating Score	2.88	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	7.76% Upside	841.46% Upside	13.05% Upside
News Sentiment Rating	Positive News See Recent ABBV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/20/2026	Piper Sandler 2 of 5 stars	David Amsellem 5 of 5 stars	Boost Target	Overweight	$298.00 ➝ $303.00	+14.07%
8/17/2026	Wells Fargo & Company 3 of 5 stars	Mohit Bansal 4 of 5 stars	Boost Target	Overweight	$295.00 ➝ $300.00	+20.38%
8/13/2026	Wolfe Research 4 of 5 stars	Alexandria Hammond Not Rated	Upgrade	Peer Perform ➝ Outperform	$300.00	+20.42%
8/11/2026	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Navann Ty Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$218.00 ➝ $247.00	-1.15%
8/5/2026	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
8/4/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C) ➝ Buy (B-)
8/4/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$261.00 ➝ $288.00	+17.73%
8/3/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$296.00	+20.69%
8/3/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$282.00 ➝ $290.00	+15.39%
8/3/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$265.00 ➝ $285.00	+13.40%
Bezos… DOOMED (Ad) A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25. Watch James Altucher's free video breakdown before the September 25 deadline.
7/29/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$275.00 ➝ $300.00	+13.86%
7/15/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$230.00 ➝ $260.00	+6.23%
7/13/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$230.00 ➝ $260.00	+5.29%
7/13/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$258.00 ➝ $300.00	+20.97%
7/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$234.00 ➝ $276.00	+12.04%
7/10/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$260.00 ➝ $280.00	+12.11%
7/9/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$260.00 ➝ $280.00	+10.68%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$300.00	+17.59%
6/23/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
5/15/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$235.00	+10.71%
4/30/2026	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
3/9/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
1/28/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$223.00	+0.58%
1/20/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luisa Hector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$275.00	+28.28%
11/13/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Sector Outperform	$280.00	+18.10%
11/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$256.00	+17.36%
8/7/2025	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$214.00	+8.98%
2/3/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$211.00 ➝ $217.00	+14.50%
11/22/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$206.00	+19.64%
11/4/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$195.00 ➝ $225.00	+16.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:02 PM ET.

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 24, 2026. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie recently reported earnings per share (EPS) of $3.65, exceeding expectations, which indicates strong financial performance and potential for growth.
The company has shown a year-over-year revenue increase of over 10%, suggesting robust demand for its products and effective business strategies.
AbbVie has a current stock price around $250, which may present a favorable entry point for investors looking for growth in the biopharmaceutical sector.
The company has a diverse product portfolio across multiple therapeutic areas, including immunology and oncology, which can mitigate risks associated with reliance on a single product.
AbbVie recently announced a quarterly dividend of $1.73 per share, translating to an annualized dividend yield of 2.6%, providing income to investors in addition to potential capital appreciation.

AbbVie
Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

AbbVie has a negative return on equity of over 422%, which may raise concerns about the company's efficiency in generating profits from shareholders' equity.
The company's dividend payout ratio is currently at 195.48%, indicating that it is paying out more in dividends than it is earning, which could be unsustainable in the long term.
Recent insider selling, including a significant transaction by an executive vice president, may signal a lack of confidence in the company's future performance.
AbbVie operates in a highly competitive biopharmaceutical market, which can lead to pricing pressures and impact profit margins.
Potential regulatory challenges and the need for ongoing investment in research and development could strain financial resources and affect profitability.

ABBV Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $275.95, with a high forecast of $303.00 and a low forecast of $223.00.

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 5 hold ratings, 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABBV shares.

According to analysts, AbbVie's stock has a predicted upside of 7.76% based on their 12-month stock forecasts.

Over the previous 90 days, AbbVie's stock had 3 upgrades by analysts.

AbbVie has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, BNP Paribas Exane, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Erste Group Bank, Guggenheim, HSBC, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Royal Bank Of Canada, Sanford C. Bernstein, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like AbbVie more than other "healthcare" companies. The consensus rating for AbbVie is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABBV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AbbVie Recommendations

MarketBeat monitors more than a dozen sources for AbbVie analyst ratings, with the most recent rating issued on 8/20/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ABBV Analyst Ratings Over Time

ABBV Analyst Recommendations By Month

ABBV Price Targets by Month

AbbVie Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

AbbVie
Bull Case

AbbVie
Bear Case

ABBV Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AbbVie Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ABBV Analyst Ratings Over Time

ABBV Analyst Recommendations By Month

ABBV Price Targets by Month

AbbVie Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

AbbVie Bull Case

AbbVie Bear Case

ABBV Forecast - Frequently Asked Questions

What is AbbVie's forecast for 2026?

Should I buy or sell AbbVie stock right now?

Does AbbVie's stock price have much upside?

Has AbbVie been upgraded by Wall Street analysts recently?

What analysts cover AbbVie?

Do Wall Street analysts like AbbVie more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AbbVie Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

AbbVie
Bull Case

AbbVie
Bear Case